Skip to main content

Heart Transplant

3
Pipeline Programs
7
Companies
50
Clinical Trials
11 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
3
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

Astellas
LEXISCANApproved
regadenoson
Astellas
Adenosine Receptor Agonist [EPC]intravenous2008

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Chong Kun Dang Pharmaceutical
1 program
1
EverolimusPhase 41 trial
Active Trials
NCT06942156Not Yet Recruiting140Est. Dec 2030
Astellas
AstellasChina - Shenyang
1 program
1
RegadenosonPhase 41 trial
Active Trials
NCT02597543Completed14Est. Jun 2016
TransMedics
TransMedicsANDOVER, MA
8 programs
OCS HeartN/A1 trial
OCS HeartN/A1 trial
OCS HeartN/A1 trial
OCS HeartN/A1 trial
OCS Heart SystemN/A1 trial
+3 more programs
Active Trials
NCT05915299Recruiting100,000Est. Aug 2033
NCT05741723Active Not Recruiting276Est. Oct 2026
NCT05096299Active Not Recruiting150Est. Aug 2026
+5 more trials
XVIVO
XVIVOSweden - Mölndal
1 program
Non-Ischemic Heart PreservationN/A1 trial
Active Trials
NCT06895070Recruiting60Est. May 2031
Natera
NateraAUSTIN, TX
1 program
ProsperaN/A1 trial
Active Trials
NCT05309382Completed147Est. Oct 2024
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
transplantN/A5 trials
Active Trials
NCT00047983Completed75Est. Apr 2004
NCT00000935Completed100Est. Jun 2003
NCT00005010CompletedEst. Mar 2004
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Chong Kun Dang PharmaceuticalEverolimus
Allergy Therapeuticstransplant
AstellasRegadenoson
Allergy Therapeuticstransplant
Allergy Therapeuticstransplant
Allergy Therapeuticstransplant
Allergy Therapeuticstransplant
Allergy Therapeuticstransplant
Allergy Therapeuticstransplant
Allergy Therapeuticstransplant
Allergy Therapeuticstransplant
Allergy Therapeuticstransplant
Allergy Therapeuticstransplant
Allergy Therapeuticstransplant
Allergy Therapeuticstransplant

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 104,184 patients across 50 trials

Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea

Start: Aug 2025Est. completion: Dec 2030140 patients
Phase 4Not Yet Recruiting

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

Start: Aug 2016Est. completion: Dec 201968 patients
Phase 4Completed

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

Start: Nov 2015Est. completion: Jun 201614 patients
Phase 4Completed

Prevention of RSV Infections in Bone Marrow Transplant Recipients

Start: Apr 1999Est. completion: May 2001120 patients
Phase 4Completed

An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens

Est. completion: Jun 2003100 patients
Phase 3Completed

Prevention of Kidney Transplant Rejection

Est. completion: Mar 2004
Phase 3Completed

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Start: Dec 2019Est. completion: Oct 2029156 patients
Phase 3Recruiting

Efficacy of Islet After Kidney Transplantation

Start: Jan 2007Est. completion: Jul 201724 patients
Phase 3Completed

Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care

Start: Aug 2001Est. completion: Jun 200460 patients
Phase 3Completed

A Study To Test An Anti-Rejection Therapy After Kidney Transplantation

Start: Nov 1999Est. completion: Mar 2004292 patients
Phase 3Terminated

Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients

Start: Nov 1997Est. completion: Mar 200390 patients
Phase 3Terminated

Belatacept in Heart Transplantation

Start: Jan 2025Est. completion: Jan 202866 patients
Phase 2Recruiting

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

Start: Sep 2024Est. completion: Jun 2030340 patients
Phase 2Recruiting

Advancing Transplantation Outcomes in Children

Start: May 2024Est. completion: Jun 2028200 patients
Phase 2Recruiting

Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation

Start: Dec 2023Est. completion: Jul 2029800 patients
Phase 2Recruiting

COVID-19 Protection After Transplant Pilot Study

Start: Aug 2021Est. completion: Mar 202381 patients
Phase 2Completed

Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation

Start: Jun 2013Est. completion: Jul 20142 patients
Phase 2Terminated

Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients

Start: Aug 2012Est. completion: Jun 2018161 patients
Phase 2Completed

Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation

Start: Nov 2010Est. completion: May 201552 patients
Phase 2Terminated

Strategies to Improve Islet Survival

Start: Dec 2006Est. completion: Feb 20145 patients
Phase 2Completed

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Start: Dec 2006Est. completion: Jul 20101 patients
Phase 2Terminated

Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients

Start: Jun 2005Est. completion: Mar 201127 patients
Phase 2Completed

Thymus Transplantation Dose in DiGeorge #932

Start: Sep 2004Est. completion: Dec 20197 patients
Phase 2Completed

Improving Transplant Options of Highly Sensitized Recipients Using IGIV-C, 10%

Start: Jun 2003Est. completion: Mar 200456 patients
Phase 2Terminated

Stem Cell Transplantation to Treat Leukocyte Adhesion Deficiency

Start: Feb 2002Est. completion: Feb 200310 patients
Phase 2Completed

Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia

Start: Sep 2001Est. completion: Nov 20032 patients
Phase 2Terminated

Modified Stem Cell Transplantation Procedure for Treating Chronic Granulomatous Disease

Start: Oct 2000Est. completion: Nov 200410 patients
Phase 2Completed

Fecal Microbiota Transplantation for Chronic Granulomatous Disease-Associated Colitis

Start: Aug 2022Est. completion: Mar 202720 patients
Phase 1/2Recruiting

Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant

Start: Dec 2017Est. completion: Mar 20245 patients
Phase 1/2Completed

Treg Therapy in Subclinical Inflammation in Kidney Transplantation

Start: Sep 2016Est. completion: Aug 202332 patients
Phase 1/2Completed

Allogeneic Hematopoietic Cell Transplantation for Severe Systemic Sclerosis

Start: Sep 2006Est. completion: Aug 20173 patients
Phase 1/2Completed

Omega-3 Fatty Acids That Affect the Immune System in Kidney Transplant Patients

Est. completion: Apr 200475 patients
Phase 1Completed

EVR and EPO for Liver Transplant Tolerance

Start: Jan 2026Est. completion: Jun 203020 patients
Phase 1Recruiting

Subcutaneous Abatacept in Renal Transplant Recipients

Start: Aug 2023Est. completion: Feb 202516 patients
Phase 1Completed

Study to Assess the Use of JSP191 in Matched Unrelated Donor Transplantation for Chronic Granulomatous Disease (CGD)

Start: Jan 2023Est. completion: Nov 20367 patients
Phase 1Active Not Recruiting

Research Study of ATG and Rituximab in Renal Transplantation

Start: Jul 2011Est. completion: Aug 201710 patients
Phase 1Terminated

Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation

Start: May 2009Est. completion: Dec 20127 patients
Phase 1Completed

Donor Stem Cell Transplantation for Congenital Immunodeficiencies

Start: Jan 2007Est. completion: Nov 201948 patients
Phase 1Completed

Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients

Start: Jun 2006Est. completion: Mar 201720 patients
Phase 1Completed

Parathyroid and Thymus Transplantation in DiGeorge #931

Start: Jan 2005Est. completion: Dec 201925 patients
Phase 1Completed

Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant

Start: Sep 2004Est. completion: Apr 20102 patients
Phase 1Completed

Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure

Start: Jun 2003Est. completion: Dec 20065 patients
Phase 1Completed

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

Start: Jun 2003Est. completion: Jul 20095 patients
Phase 1Completed

Thymus Transplantation With Immunosuppression

Start: Jul 2002Est. completion: Dec 201915 patients
Phase 1Completed

Stem Cell Transplant Following Low-Intensity Chemotherapy to Treat Chronic Granulomatous Disease

Start: Apr 1998Est. completion: Feb 200560 patients
Phase 1Completed

Enhancing Heart Allograft Function With the OCS Heart System Trial

Start: Jan 2026Est. completion: Jul 2027655 patients
N/ARecruiting
NCT06895070XVIVONon-Ischemic Heart Preservation

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

Start: Jul 2025Est. completion: May 203160 patients
N/ARecruiting

Kidney Transplantation From Donors With HIV: Impact on Rejection and Long-Term Outcomes (Expanding HOPE Kidney)

Start: May 2024Est. completion: Sep 2029200 patients
N/ARecruiting

Fecal Microbiota Transplant National Registry

Start: Oct 2023Est. completion: Oct 203210 patients
N/AEnrolling By Invitation

US National OCS Heart Perfusion (OHP) Registry

Start: Aug 2023Est. completion: Aug 2033100,000 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

11 actively recruiting trials targeting 104,184 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.